Resistenz umgehen, Prognose verbessern – Myocet® beim AIDS-assoziierten Non-Hodgkin-Lymphom

Publisher： Karger

E-ISSN： 2296-5262|27|5|514-515

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.27, Iss.5, 2004-10, pp. : 514-515

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Primäres Hodgkin-Lymphom des Kolons

By Hansen T.   Hartmann F.   Hiller W.   Schütz M.   Oschlies I.  

Der Pathologe, Vol. 35, Iss. 2, 2014-03 ,pp. : 191-195

Springer Publishing Company

Access to resources Recommend Favorite

Myocet® zur Therapieoptimierung beim Mammakarzinom: Hohe Wirksamkeit, geringe Kardiotoxizität

By  

Oncology Research and Treatment, Vol. 26, Iss. 4, 2003-09 ,pp. : 406-407

Karger

Access to resources Recommend Favorite

Deutsche Hodgkin-Lymphom-Studiengruppe (DHSG): 20 Jahre Diagnostik, Therapie und Nachsorge von Patienten mit Morbus Hodgkin

By  

Oncology Research and Treatment, Vol. 24, Iss. 1, 2001-03 ,pp. : 35-48

Karger

Access to resources Recommend Favorite

Non-Hodgkin Lymphomas Concurrent with HHV8-Associated Kaposi’s Sarcoma in the Same Lymph Node in AIDS and Non-AIDS Patients

By  

Acta Haematologica, Vol. 118, Iss. 1, 2007-05 ,pp. : 47-52

Karger

Access to resources Recommend Favorite

U-HO1: Eine neue Zelllinie, abstammend von einem primär therapierefraktären klassischen Hodgkin-Lymphom

By Möller P.   Mader A.   Barth T.F.E.   Brüderlein S.  

Der Pathologe, Vol. 29, Iss. 2, 2008-11 ,pp. : 317-318

Springer Publishing Company

Access to resources Recommend Favorite